Please use this identifier to cite or link to this item:
Title: Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer's disease.
Austin Authors: Soudy, Rania;Patel, Aarti;Fu, Wen;Kaur, Kamaljit;MacTavish, David;Westaway, David;Davey, Rachel A;Zajac, Jeffrey D ;Jhamandas, Jack
Affiliation: Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada
Department of Medicine (Neurology), Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
Chapman University School of Pharmacy, Irvine, California, USA
Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada
Faculty of Pharmacy, Cairo University, Cairo, Egypt
Medicine (University of Melbourne)
Issue Date: Jan-2017
Date: 2016-12-10
Publication information: Alzheimer's & Dementia (New York, N. Y.) 2017; 3(1): 44-56
Abstract: Amylin receptor serves as a portal for the expression of deleterious effects of amyloid β-protein (Aβ), a key pathologic hallmark of Alzheimer's disease. Previously, we showed that AC253, an amylin receptor antagonist, is neuroprotective against Aβ toxicity in vitro and abrogates Aβ-induced impairment of hippocampal long-term potentiation. Amyloid precursor protein-overexpressing TgCRND8 mice received intracerebroventricularly AC253 for 5 months. New cyclized peptide cAC253 was synthesized and administered intraperitoneally three times a week for 10 weeks in the same mouse model. Cognitive functions were monitored, and pathologic changes were quantified biochemically and immunohistochemically. AC253, when administered intracerebroventricularly, improves spatial memory and learning, increases synaptic integrity, reduces microglial activation without discernible adverse effects in TgCRND8 mice. cAC253 demonstrates superior brain permeability, better proteolytic stability, and enhanced binding affinity to brain amylin receptors after a single intraperitoneal injection. Furthermore, cAC253 administered intraperitoneally also demonstrates improvement in spatial memory in TgCRND8 mice. Amylin receptor is a therapeutic target for Alzheimer's disease and represents a disease-modifying therapy for this condition.
DOI: 10.1016/j.trci.2016.11.005
ORCID: 0000-0001-5121-0209
Journal: Alzheimer's & Dementia (New York, N. Y.)
PubMed URL: 29067318
ISSN: 2352-8737
Type: Journal Article
Subjects: AC253 peptide
Alzheimer's disease
Amylin receptor
Amyloid β
Brain penetration
In vivo imaging
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 21, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.